

MUGARD (carbomer; glycerin; polysorbate)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
2/2/21, 8/3/21, 2/1/22, 1/31/23, 2/13/24

Mugard is an oral rinse which acts as a mucoadhesive and forms a protective coating over the oral mucosa. Other brand names for this product include Gelclair, Mucotrol, Orafate and PrThelial

Authorization: For the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers.

Dosing: Pour 5mL into mouth and rinse entire oral cavity for 30–60 seconds, or longer. May use up to 10mL to fully coat inside of mouth. After rinsing, expel or swallow. Repeat 4–6 times/day. Avoid eating or drinking for at least 1 hour after rinsing. Not recommended for children.

PRECAUTIONS: Do not dilute. Avoid food or liquids for at least one hour after use. May decrease absorption of sublingually administered medications.

DRUG INTERACTIONS: none known

REFERENCES

1. MuGard [product information]. Waltham, MA: AMAG Pharmaceuticals Inc; December 2014
2. Vokurka S, Skardova J, Hruskova R, et al, “The Effect of Polyvinylpyrrolidone-Sodium Hyaluronate Gel (Gelclair) on Oral Microbial Colonization and Pain Control Compared With Other Rinsing Solutions in Patients With Oral Mucositis After Allogeneic Stem Cells Transplantation,” *Med Sci Monit*, 2011, 17(10):CR572-6.
3. Barber C, Powell R, Ellis A, et al, “Comparing Pain Control and Ability to Eat and Drink With Standard Therapy vs Gelclair: A Preliminary, Double Centre, Randomized Controlled Trial on Patients With Radiotherapy-Induced Oral Mucositis,” *Support Care Cancer*, 2007, 15(4):427-40.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19
 Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/18/20
 Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/2/21
 Date Reviewed/No Updates: 8/3/21 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 8/3/21
 Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/1/22
 Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/31/23
 Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/13/24

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated description and references
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review